Crispr Therapeutics

Yahoo Finance • 4 days ago

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. And based on Wall Street's projections, several nota... Full story

Yahoo Finance • 4 days ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

It's shaping up to be another rocky week of trading, and the volatility will probably keep Cathie Wood busy. The co-founder, CEO, and ace stock picker for Ark Invest tends to be active when the market's moving one way or another. She bough... Full story

Yahoo Finance • 8 days ago

Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March

Shares of early-stage biotech stocks, including Biohaven(NYSE: BHVN), Recursion Pharmaceuticals(NASDAQ: RXRX), and CRISPR Therapeutics(NASDAQ: CRSP), plunged in March, with the stocks down 35.3%, 29.6%, and 22.5%, respectively, according t... Full story

Yahoo Finance • 15 days ago

CRISPR Therapeutics Announces Transition of Chief Operating Officer

ZUG, Switzerland and BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief... Full story

Yahoo Finance • 19 days ago

2 Beaten-Down Stocks to Buy on the Dip

While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant that title regardless of what's transpired in 2025. Among them are CRISPR Therapeutics(NASDAQ: CRSP) and Merck(NY... Full story

Yahoo Finance • 2 months ago

Street Calls of the Week

Investing.com -- Here is your Pro Recap of the top takeaways from Wall Street analysts for the past week. InvestingPro subscribers always get first dibs on market-moving AI analyst comments. Upgrade today! Kraft-Heinz Co What happened?... Full story

Yahoo Finance • 2 months ago

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

-2025 is poised to be a catalyst-rich year with key updates across several programs- -Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 au... Full story

Yahoo Finance • 6 months ago

3 Bargain Stocks to Buy in a Market That's Priced for Perfection

How richly valued are stocks right now? Legendary investor Warren Buffett has built Berkshire Hathaway's cash stockpile up to roughly $277 billion. When Buffett is sitting on that much cash because he can't find appealing investments to bu... Full story

Yahoo Finance • 7 months ago

3 Dirt Cheap Stocks to Buy Right Now

By most metrics, the stock market is priced at a premium these days. But that doesn't mean bargains can't still be found. Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why th... Full story

Yahoo Finance • 7 months ago

3 Monster Biotech Stocks to Buy Before 2025

Many investors rightfully identify biotech stocks as being riskier than average, and those stocks certainly have a habit of earning their reputation. Still, there are a few up-and-coming biotechs that have revenue and a clear path to gener... Full story

Yahoo Finance • 8 months ago

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Misses Revenue Estimates

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.49 per share versus the Zacks Consensus Estimate of a loss of $1.37. This compares to loss of $0.98 per share a year ago. These figures are adjusted for non-recurring items... Full story

Yahoo Finance • 8 months ago

Prediction: CRISPR Therapeutics Stock Could Be a Millionaire-Maker

Gene editing, in which researchers manipulate patients' genetic code to treat genetic illnesses, has been around for a couple of decades. But it has made incredible progress in the past five years. CRISPR Therapeutics(NASDAQ: CRSP), a mid-... Full story

Yahoo Finance • 9 months ago

3 Monster Stocks in the Making to Buy Right Now

California's giant redwood trees were once tiny sprouts or seeds. Likewise, the world's biggest companies were once much smaller. Trees and companies can grow significantly over time -- at least some of them. Three Motley Fool contributor... Full story

Yahoo Finance • 9 months ago

1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid

It hasn't been a stellar year so far for biotech companies. The industry, as measured by the SPDR S&P Biotech ETF, is up just 4% since January, significantly lagging the S&P 500 's nearly 17% gain. Of course, it's not hard to find stocks... Full story

Yahoo Finance • 10 months ago

Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought

Cathie Wood is known for two things: picking out innovators that will go on to score a win over the long run, and getting in on these stocks at a great price. The founder and chief executive officer of Ark Invest doesn't mind going against... Full story

Yahoo Finance • 10 months ago

Cathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You?

Via her ARK Innovation ETF(NYSEMKT: ARKK), portfolio manager Cathie Wood makes a lot of biotech bets, often on companies that are at the cutting edge of innovation in science and technology. Businesses like that tend to have volatile and t... Full story

Yahoo Finance • 11 months ago

3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow

As its shareholders already know, CRISPR Therapeutics (NASDAQ: CRSP) has quite a few opportunities on the table. Between its commercialized medicine, a pipeline that's packed with chances to mint blockbuster drugs, and plenty of financial... Full story

Yahoo Finance • 11 months ago

CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

CRISPR Therapeutics AG -Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A., promoted to Chief Operating Officer- ZUG, Switzerland and BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CR... Full story

Yahoo Finance • 12 months ago

Cathie Wood’s Latest Stock Portfolio: Top 10 Stock Picks

In this piece, we will take a look at Cathie Wood's latest investment portfolio and her top ten stock picks. If you want to skip our coverage of Ms. Wood, her investment firm, and the latest stock market news, then you can take a look at C... Full story

Yahoo Finance • 12 months ago

3 Magnificent Stocks That Could Double or More by 2030

Does a 100% return in less than seven years sound pretty good? Most investors would probably say so. But which stocks are good candidates to achieve such a gain? Three Motley Fool contributors think they've found magnificent stocks that c... Full story